Lurasidone

Summary

Lurasidone (CHEMBL1237021) is an approved small-molecule adrenergic antagonist (ATC N05AE05) targeting HTR7, HTR1A, and DRD2; indicated across 8 conditions including psychotic disorder and autism.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05AE05
• Targets: 6 (HTR7, HTR1A, DRD2…)
• Indications: 8 conditions
• Clinical trials: 68
• Chemistry: 492.7 Da · C28H36N4O2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1237021
Name	Lurasidone
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	213046
ChEBI	CHEBI:70735
ATC	N05AE05
Molecular formula	C28H36N4O2S
Molecular weight	492.7
InChIKey	PQXKDMSYBGKCJA-CVTJIBDQSA-N

SMILES: C1CC[C@H]([C@@H](C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)[C@H]6[C@@H]7CC[C@@H](C7)[C@H]6C5=O

IUPAC name: (1R,2S,6R,7S)-4-[[(1R,2R)-2-[[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl]cyclohexyl]methyl]-4-azatricyclo[5.2.1.02,6]decane-3,5-dione

ChEBI definition: An N-arylpiperazine that is (3aR,4S,7R,7aS)-2-{[(1R,2R)-2-(piperazin-1-ylmethyl)cyclohexyl]methyl}hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione in which position N4 of the piperazine ring is substituted by a 1,2-benzothiazol-3-yl group. Lurasidone is used (generally as the hydrochloride salt) as an atypical antipsychotic for the treatment of schizophrenia.

Pharmacological roles (ChEBI): adrenergic antagonist, dopaminergic antagonist, serotonergic antagonist, second generation antipsychotic.

Also known as: Lurasidona, Lurasidone, SM-13496 FREE BASE, LURASIDONE, lurasidone, Lurasidone HCl

Parent form; salt/anhydrous children: CHEMBL1615372

Patent coverage: 1,018 distinct patent families (2,517 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 2,310 (92%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
HTR7	5-HT7 receptor	Antagonist	9.31	0.8%	P34969
HTR1A	5-HT1A receptor	Partial agonist	8.17	0%	P08908
DRD2	D2 receptor	Antagonist	8.77	0%	P14416
ADRA2A	α2A-adrenoceptor	Antagonist	7.4	0.1%	P08913
ADRA2C	α2C-adrenoceptor	Antagonist	8	0%	P18825
HTR2A	5-HT2A receptor	Antagonist	8.69	0%	P28223

Broader ChEMBL bioactivity targets: 29 (assay-derived). Sample: 5-hydroxytryptamine receptor 2B, Alpha-2A adrenergic receptor, Cholecystokinin receptor type A, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, Sodium channel protein type 5 subunit alpha, D(1A) dopamine receptor, Thromboxane A2 receptor, Muscarinic acetylcholine receptor M2, 5-hydroxytryptamine receptor 1A.

Bioactivity

ChEMBL activities: 36 potent at pChembl ≥ 5 of 45 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HTR7	9.3	Ki	0.5	nM	CHEMBL_ACT_18891537
HTR7	9.3	Ki	0.5	nM	CHEMBL_ACT_20711558
P61169	8.78	Ki	1.68	nM	CHEMBL_ACT_20711470
DRD2	8.77	Ki	1.7	nM	CHEMBL_ACT_18891557
HTR2A	8.7	Ki	2	nM	CHEMBL_ACT_18891569
P14842	8.69	Ki	2.03	nM	CHEMBL_ACT_20711440
DRD3	8.38	AC50	4.2	nM	CHEMBL_ACT_25194760
HTR1A	8.17	Ki	6.7	nM	CHEMBL_ACT_18891606
P19327	8.17	Ki	6.75	nM	CHEMBL_ACT_20711455
HTR1A	8.08	AC50	8.4	nM	CHEMBL_ACT_25165268
HTR7	7.8	IC50	15.72	nM	CHEMBL_ACT_23176969
DRD2	7.75	AC50	18	nM	CHEMBL_ACT_25140489
HTR2A	7.64	AC50	23	nM	CHEMBL_ACT_25225313
HTR1A	7.2	AC50	63	nM	CHEMBL_ACT_25216134
Q01827	7.16	AC50	69.9	nM	CHEMBL_ACT_25197379
HTR2B	7.15	AC50	71	nM	CHEMBL_ACT_25227670
ADRA1A	7.12	AC50	75.4	nM	CHEMBL_ACT_25219054
HTR1A	7.02	AC50	95	nM	CHEMBL_ACT_25165668
DRD1	6.88	AC50	131	nM	CHEMBL_ACT_25115454
ADRA1A	6.88	AC50	132	nM	CHEMBL_ACT_25218177
ADRA2A	6.67	AC50	215.5	nM	CHEMBL_ACT_25156673
ADRA2B	6.64	AC50	230	nM	CHEMBL_ACT_25143855
DRD3	6.37	AC50	430	nM	CHEMBL_ACT_25193681
ADRA2A	6.3	AC50	500	nM	CHEMBL_ACT_25220038
KCNH2	6.28	AC50	530	nM	CHEMBL_ACT_25118085
ADRA2C	5.96	AC50	1100	nM	CHEMBL_ACT_25148032
ACHE	5.89	AC50	1300	nM	CHEMBL_ACT_25142214
ADRA2A	5.78	AC50	1661	nM	CHEMBL_ACT_25157083
CHRM2	5.68	AC50	2100	nM	CHEMBL_ACT_25213882
DRD1	5.51	AC50	3100	nM	CHEMBL_ACT_25181269

Target pathways

Aggregated over 6 target gene(s): HTR7, HTR1A, DRD2, ADRA2A, ADRA2C, HTR2A.

Top Reactome pathways

24 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	5	ADRA2A, ADRA2C, HTR1A, HTR2A, HTR7
Signaling by GPCR	5	ADRA2A, ADRA2C, HTR1A, HTR2A, HTR7
Class A/1 (Rhodopsin-like receptors)	5	ADRA2A, ADRA2C, HTR1A, HTR2A, HTR7
Amine ligand-binding receptors	5	ADRA2A, ADRA2C, HTR1A, HTR2A, HTR7
GPCR ligand binding	5	ADRA2A, ADRA2C, HTR1A, HTR2A, HTR7
GPCR downstream signalling	4	ADRA2A, ADRA2C, HTR2A, HTR7
Serotonin receptors	3	HTR1A, HTR2A, HTR7
Hemostasis	2	ADRA2A, ADRA2C
Metabolism	2	ADRA2A, ADRA2C
Integration of energy metabolism	2	ADRA2A, ADRA2C
Adrenoceptors	2	ADRA2A, ADRA2C
Adrenaline signalling through Alpha-2 adrenergic receptor	2	ADRA2A, ADRA2C
Metabolism of proteins	2	ADRA2A, ADRA2C
Adrenaline,noradrenaline inhibits insulin secretion	2	ADRA2A, ADRA2C
G alpha (i) signalling events	2	ADRA2A, ADRA2C
G alpha (z) signalling events	2	ADRA2A, ADRA2C
Regulation of insulin secretion	2	ADRA2A, ADRA2C
Surfactant metabolism	2	ADRA2A, ADRA2C
Platelet activation, signaling and aggregation	2	ADRA2A, ADRA2C
Platelet Aggregation (Plug Formation)	2	ADRA2A, ADRA2C
Dopamine receptors	1	DRD2
G alpha (q) signalling events	1	HTR2A
G alpha (s) signalling events	1	HTR7
RHOBTB3 ATPase cycle	1	HTR7

Dominant GO biological processes

GO term	Targets
signal transduction	6
G protein-coupled receptor signaling pathway	6
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	3
chemical synaptic transmission	3
G protein-coupled serotonin receptor signaling pathway	3
positive regulation of cell population proliferation	3
regulation of vasoconstriction	3
negative regulation of insulin secretion	3
presynaptic modulation of chemical synaptic transmission	3
serotonin receptor signaling pathway	2
adult behavior	2
adenylate cyclase-activating G protein-coupled receptor signaling pathway	2
temperature homeostasis	2
intracellular calcium ion homeostasis	2
response to xenobiotic stimulus	2

Indications & clinical

Indications

8 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
psychotic disorder	3	MONDO:0005485	EFO:0005407
autism	3	MONDO:0005260	EFO:0003758
schizoaffective disorder	3	MONDO:0005487	EFO:0005411
major depressive disorder	3	MONDO:0002009	MONDO:0002009
depressive disorder	3	MONDO:0002050	MONDO:0002050
bipolar disorder	3	MONDO:0004985	EFO:0009963

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 68.

Phase distribution

Phase	Trials
PHASE3	31
PHASE1	11
PHASE4	10
Not specified	8
PHASE2	6
PHASE2/PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06433635	PHASE4	ACTIVE_NOT_RECRUITING	Sequential Multiple Assignment Randomized Trial for Bipolar Depression
NCT01569659	PHASE4	COMPLETED	High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia
NCT02199743	PHASE4	COMPLETED	Lurasidone Effects on Tissue Glutamate in Schizophrenia
NCT02282085	PHASE4	UNKNOWN	Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia
NCT03304457	PHASE4	COMPLETED	Lurasidone Vs Olanzapine on Neurotrophic Biomarkers and Cardiometabolic Parameters in Unmedicated Schizophrenia
NCT03393026	PHASE4	COMPLETED	A Study of Lurasidone HCl in Subjects With Schizophrenia
NCT03902613	PHASE4	COMPLETED	18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder
NCT05011669	PHASE4	COMPLETED	The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia
NCT05213143	PHASE4	TERMINATED	The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine
NCT05351736	PHASE4	UNKNOWN	Impact of Structural and Myelin Abnormalities on Cognitive Impairments in Recent-onset Schizophrenia - Before and After Lurasidone Treatment (MARYLU)
NCT00549718	PHASE3	COMPLETED	Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia
NCT00615433	PHASE3	COMPLETED	Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia
NCT00641745	PHASE3	COMPLETED	Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia
NCT00789698	PHASE3	COMPLETED	Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia
NCT00790192	PHASE3	COMPLETED	Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
NCT00868452	PHASE3	COMPLETED	Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on)
NCT00868699	PHASE3	COMPLETED	Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
NCT00868959	PHASE3	COMPLETED	Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
NCT01143077	PHASE3	COMPLETED	A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents
NCT01143090	PHASE3	COMPLETED	A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder
NCT01284517	PHASE3	COMPLETED	Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
NCT01358357	PHASE3	COMPLETED	Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex
NCT01421134	PHASE3	COMPLETED	Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose
NCT01423240	PHASE3	WITHDRAWN	Major Depressive Disorder With Mixed Features
NCT01423253	PHASE3	COMPLETED	Major Depressive Disorder With Mixed Features - Extension
NCT01435928	PHASE3	COMPLETED	PEARL Schizophrenia Maintenance
NCT01485640	PHASE3	COMPLETED	Lurasidone Extended Use Study
NCT01566162	PHASE3	COMPLETED	A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
NCT01575561	PHASE3	COMPLETED	This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296
NCT01821378	PHASE3	COMPLETED	Lurasidone Low-Dose - High-Dose Study Study
NCT01911429	PHASE3	COMPLETED	Pediatric Schizophrenia Efficacy and Safety Study
NCT01911442	PHASE3	COMPLETED	Lurasidone Pediatric Autism Study
NCT01914393	PHASE3	COMPLETED	Pediatric Open-Label Extension Study
NCT01979679	PHASE3	COMPLETED	A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With Lurasidone
NCT02002832	PHASE3	COMPLETED	A Clinical Trial of Lurasidone in Treatment of Schizophrenia
NCT02046369	PHASE3	COMPLETED	Lurasidone Pediatric Bipolar Study
NCT02147379	PHASE3	COMPLETED	Lurasidone and Cognition in Bipolar I Disorder
NCT02731612	PHASE3	COMPLETED	Study of the Efficacy of Lurasidone in Cognitive Functioning in Bipolar Patients
NCT03395392	PHASE2/PHASE3	COMPLETED	NRX-101 for Bipolar Depression With Subacute Suicidal Ideation
NCT03396068	PHASE3	UNKNOWN	NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 1 clinical and 5 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

817 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
BREXPIPRAZOLE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
CLOZAPINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
Dihydroergotamine	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
OLANZAPINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
PRAMIPEXOLE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
TAMSULOSIN	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
TEGASEROD	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
AMOXAPINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
CARIPRAZINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
CARVEDILOL	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
CISAPRIDE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
CYPROHEPTADINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
DOXEPIN	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
FLUPHENAZINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
HALOPERIDOL	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
LOXAPINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
METHYSERGIDE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
MIANSERIN	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
NEFAZODONE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
PERPHENAZINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
PROMAZINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
QUETIAPINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
RISPERIDONE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
THIORIDAZINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
THIOTHIXENE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
ZIPRASIDONE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
FANANSERIN	ChEMBL	Phase 2	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
IPSAPIRONE	ChEMBL	Phase 2	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
METERGOLINE	ChEMBL	Phase 2	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
PIZOTYLINE	ChEMBL	Phase 2	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
RITANSERIN	ChEMBL	Phase 2	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
SPIPERONE	ChEMBL	Phase 2	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
SPIRAMIDE	ChEMBL	Phase 2	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
SPIROXATRINE	ChEMBL	Phase 2	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
Pyrazinamide	PubChem	Approved	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
chenodiol	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A
DESLORATADINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A
Fidaxomicin	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A
GENTIAN VIOLET	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A
PALIPERIDONE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR2A, HTR7
Propoxyphene	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A
ACETOPHENAZINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A
AMISULPRIDE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR2A, HTR7
AMITRIPTYLINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A
AMLODIPINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A
APOMORPHINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A
ASENAPINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A
AZELASTINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR2A, HTR7
BAZEDOXIFENE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A
BENPERIDOL	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A
BOSUTINIB	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A
BROMOCRIPTINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A
BROMPERIDOL	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A
BUSPIRONE	ChEMBL	Phase 4 (approved)	ADRA2C, DRD2, HTR1A, HTR2A, HTR7
CABERGOLINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A
CHLORHEXIDINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A
CINACALCET	ChEMBL	Phase 4 (approved)	ADRA2C, DRD2, HTR1A, HTR2A, HTR7